Details of Disease

General Information of Disease (ID: DIS1A2CS)

Disease Name	Multi-drug resistant tuberculosis
Synonyms	multidrug-resistant TB; MDR-TB
Disease Class	MG50-MG52: Antimicrobial drug resistance
Definition	A type of drug-resistant tuberculosis that is resistant to both rifampicin and isoniazid, the two most powerful anti-TB drugs.
Disease Hierarchy	DIS5BUFB: Drug-resistant tuberculosis DIS1A2CS: Multi-drug resistant tuberculosis
ICD Code	ICD-11 ICD-11: MG52.00 Expand ICD-9 1.00E+25
Disease Identifiers	MONDO ID MONDO_0005861 MESH ID D018088 UMLS CUI C0206526 MedGen ID 60163 SNOMED CT ID 423092005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bedaquiline	DM3906J	Approved	Small molecular drug	[1]
Delamanid	DMXE76K	Approved	Small molecular drug	[2]
Perchlozone	DM2KZ7I	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MAS1	TTOISYB	Limited	Biomarker	[4]
RPS12	TTD81N3	Limited	Biomarker	[5]
ABCA4	TTLB52K	Strong	Biomarker	[6]
RNF34	TTEWDK1	Strong	Biomarker	[7]
------------------------------------------------------------------------------------

This Disease Is Related to 12 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CHAMP1	OTBGWU86	Limited	Biomarker	[8]
FASTK	OTTHFZMP	Limited	Biomarker	[9]
IL12RB1	OTM1IJO2	Limited	Altered Expression	[10]
LRSAM1	OTOKWR6C	Limited	Biomarker	[11]
MOV10L1	OTP978LK	Limited	Biomarker	[8]
SIT1	OT7MDF09	Limited	Genetic Variation	[12]
INHA	OT7HWCO3	Disputed	Biomarker	[13]
BCAR1	OTKT2C2N	Strong	Biomarker	[14]
EMB	OT67E3Q1	Strong	Biomarker	[15]
GNA12	OT3IRZH3	Strong	Biomarker	[6]
NCAPG2	OTZYENKO	Strong	Biomarker	[16]
RHOF	OTPA3F8Q	Strong	Biomarker	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 12 DOT(s)

References

1	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
2	Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
3	Focus on perchlozone, an anti-tuberculosis drug from the Russian Federation. Ceska Slov Farm. Winter 2020;69(5-6):203-210.
4	Evaluation of efficiency of nested multiplex allele-specific PCR assay for detection of multidrug resistant tuberculosis directly from sputum samples.Lett Appl Microbiol. 2016 May;62(5):411-8. doi: 10.1111/lam.12564.
5	Characterization of mutations conferring streptomycin resistance to multidrug-resistant Mycobacterium tuberculosis isolates from Myanmar.Tuberculosis (Edinb). 2018 Jul;111:8-13. doi: 10.1016/j.tube.2018.05.003. Epub 2018 May 8.
6	What happened to patients with RMP-resistant/MDR-TB in Zambia reported as lost to follow-up from 2011 to 2014?.Int J Tuberc Lung Dis. 2017 Aug 1;21(8):887-893. doi: 10.5588/ijtld.16.0933.
7	Benzofuran-isatin-imine hybrids tethered via different length alkyl linkers: Design, synthesis and invitro evaluation of anti-tubercular and anti-bacterial activities as well as cytotoxicity.Eur J Med Chem. 2019 Mar 1;165:323-331. doi: 10.1016/j.ejmech.2019.01.042. Epub 2019 Jan 22.
8	Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).Trials. 2018 Dec 20;19(1):693. doi: 10.1186/s13063-018-3070-0.
9	Turning Off the Tap: Using the FAST Approach to Stop the Spread of Drug-Resistant Tuberculosis in the Russian Federation.J Infect Dis. 2018 Jul 13;218(4):654-658. doi: 10.1093/infdis/jiy190.
10	Severe BCG-osis Misdiagnosed as Multidrug-Resistant Tuberculosis in an IL-12R1-Deficient Peruvian Girl.J Clin Immunol. 2018 Aug;38(6):712-716. doi: 10.1007/s10875-018-0535-6. Epub 2018 Jul 23.
11	Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.Int J Tuberc Lung Dis. 2019 Sep 1;23(9):1005-1011. doi: 10.5588/ijtld.18.0626.
12	Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection.Am J Trop Med Hyg. 2016 Dec 7;95(6):1239-1246. doi: 10.4269/ajtmh.15-0711. Epub 2016 Oct 24.
13	Characterisation of drug resistance-associated mutations among clinical multidrug-resistant Mycobacterium tuberculosis isolates from Hebei Province, China.J Glob Antimicrob Resist. 2019 Sep;18:168-176. doi: 10.1016/j.jgar.2019.03.012. Epub 2019 Mar 27.
14	Genetic diversity of Mycobacterium tuberculosis Central Asian Strain isolates from Nepal and comparison with neighboring countries.Trans R Soc Trop Med Hyg. 2019 Apr 1;113(4):203-211. doi: 10.1093/trstmh/try136.
15	Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.Microb Drug Resist. 2018 Sep;24(7):923-931. doi: 10.1089/mdr.2017.0294. Epub 2018 Jan 16.
16	Design, synthesis and in vitro anti-mycobacterial activities of homonuclear and heteronuclear bis-isatin derivatives.Fitoterapia. 2018 Jun;127:383-386. doi: 10.1016/j.fitote.2018.03.018. Epub 2018 Apr 6.